Bayer’s innovative non-steroidal heart failure drug, Kerendia (finerenone), has received a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for its use within the National Health Service (NHS) in England. This landmark decision targets patients suffering from chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), a patient population that has historically faced limited effective treatment options. The availability of Kerendia is anticipated to significantly impact the management of heart failure, which remains one of the leading causes of avoidable hospitalisations across England, placing a considerable burden on healthcare resources and diminishing patient quality of life.
The final draft guidance from NICE, expected in August 2026, will pave the way for eligible English patients to access this next-generation mineralocorticoid receptor antagonist (MRA). This marks a crucial step forward in addressing a complex and prevalent condition, offering a new therapeutic pathway to an estimated 280,000 individuals across England who are likely to benefit from Kerendia. The drug’s unique pharmacological profile and its potential to improve patient outcomes underscore its importance in the evolving landscape of cardiovascular medicine.
Understanding Kerendia: A Novel Approach to Heart Failure
Kerendia, with its active compound finerenone, distinguishes itself as a selective, non-steroidal mineralocorticoid receptor antagonist. Unlike its steroidal predecessors, such as spironolactone and eplerenone, finerenone’s non-steroidal structure allows for a more targeted action and a potentially reduced risk of adverse effects commonly associated with older MRAs. The drug works by reducing vascular inflammation and mitigating mineralocorticoid signalling-induced scarring in the muscular layer of the heart wall, a process known as myocardial fibrosis. Furthermore, Kerendia contributes to its therapeutic effects by decreasing sodium retention in the kidneys, thereby alleviating the heart’s workload in pumping excess fluid.
The clinical significance of Kerendia lies in its ability to address the multifaceted pathology of heart failure, particularly in patients with HFpEF and HFmrEF. These conditions are characterized by the heart’s inability to relax properly and fill with blood, or by a mildly impaired pumping function, respectively. Historically, treatment options for HFpEF have been limited, making Kerendia’s approval a particularly welcome development for clinicians and patients alike. Its selective action on mineralocorticoid receptors aims to interrupt the detrimental cycle of inflammation and fibrosis that contributes to disease progression.
One of the key advantages highlighted by Bayer and NICE is Kerendia’s potential to treat a wider patient population. Its non-steroidal nature means it can be considered for patients who might be at higher risk of side effects, such as hyperkalemia, with traditional steroidal MRAs, especially those with co-existing kidney impairment. Moreover, Bayer has designed finerenone to be more selective, reducing interference with sex hormone activity and thus lowering the incidence of associated side effects, such as gynecomastia, which can be a concern with older MRA therapies. This improved tolerability profile could lead to better patient adherence and, consequently, more effective long-term management of heart failure.
The Pervasive Challenge of Heart Failure in England
Heart failure represents a profound public health challenge in England, affecting a substantial portion of the population and placing immense strain on the NHS. NICE estimates that approximately 635,000 patients across England are living with heart failure. A critical aspect of this demographic is that nearly half of these individuals present with preserved or mildly reduced ejection fraction, the very cohort targeted by Kerendia. This highlights a significant unmet medical need that finerenone is now poised to address.
The human and economic costs of heart failure are staggering. Between 2023 and 2024, heart failure was linked to an estimated 100,000 hospitalisations in England. These admissions are often unplanned and emergency-driven, pointing to the chronic, progressive nature of the disease and the challenges in managing it effectively in community settings. Such frequent hospitalisations not only severely impact the patient’s quality of life, leading to recurrent symptoms, reduced physical activity, and increased mortality risk, but also incur substantial direct costs for the NHS, including emergency care, bed days, and subsequent follow-up. Indirect costs, such as loss of productivity and caregiver burden, further amplify the societal impact of this condition.
The high rates of avoidable hospital admissions underscore the urgent need for effective preventative and treatment-based interventions that can stabilize patients, improve their symptoms, and ultimately reduce the likelihood of acute exacerbations requiring inpatient care. The introduction of therapies like Kerendia, which can address the underlying pathophysiology of heart failure and potentially reduce these critical events, is therefore a significant step towards alleviating the burden on both patients and the healthcare system.
A Chronology of Kerendia’s Journey and Evolving Treatment Paradigms
Kerendia’s latest NICE recommendation is part of a broader trajectory for the drug and reflects an evolving understanding of heart failure management. Its journey to widespread availability in England has several key milestones:
- 2023: Initial NICE Recommendation for CKD/T2D: Kerendia first gained NICE’s approval for use in adult patients with stage 3 or 4 chronic kidney disease (CKD) linked to type 2 diabetes, provided they exhibited a presence of the blood protein albumin in their urine. This initial approval established finerenone’s efficacy in protecting renal function in a high-risk population, demonstrating its anti-inflammatory and anti-fibrotic properties beyond pure cardiovascular benefits. This earlier success laid foundational evidence for its broader application.
- 2023: Emergence of SGLT2 Inhibitors for HFpEF: The year 2023 also saw other significant advancements in heart failure treatment. SGLT2 inhibitors, such as Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Forxiga (dapagliflozin), received NICE’s green light for use in chronic heart failure with preserved or mildly reduced ejection fraction. These approvals marked a paradigm shift, as SGLT2 inhibitors, originally developed for diabetes, demonstrated remarkable cardiovascular and renal benefits in heart failure, including HFpEF. Kerendia will now join this expanded arsenal of evidence-based therapies, complementing existing treatments that include legacy MRAs and loop diuretics for fluid management.
- March 2026: MHRA and NICE Aligned Pathway: In a broader regulatory context, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE launched an aligned pathway designed to expedite the medicines regulation process. This initiative aims to streamline the assessment and approval of promising new treatments, potentially reducing the time it takes for innovative drugs like Kerendia to reach patients. This policy development underscores a commitment to accelerating patient access to cutting-edge therapies in the UK.
- August 2026: Expected Final Draft Guidance: The current NICE recommendation for Kerendia in HFpEF/HFmrEF is awaiting its final draft guidance, expected in August 2026. Once published, this will formalise the drug’s inclusion in NHS treatment protocols, making it accessible to eligible patients across England.
The scientific foundation for Kerendia’s use in heart failure with preserved or mildly reduced ejection fraction largely stems from pivotal clinical trials. Notably, the FINEARTS-HF study investigated the efficacy and safety of finerenone in patients with symptomatic HFpEF with an ejection fraction ≥40%. This large-scale, placebo-controlled trial provided robust evidence demonstrating finerenone’s ability to reduce the risk of cardiovascular death and total heart failure events (hospitalizations and urgent visits), thereby supporting its use in this challenging patient population. These clinical trial results were instrumental in informing NICE’s positive appraisal.
Voices on the Recommendation: Stakeholder Reactions
The NICE recommendation for Kerendia has been met with positive anticipation from various stakeholders within the healthcare community. Helen Knight, NICE’s director of medicines evaluation, articulated the dual benefits of this approval, stating that Kerendia "not only holds the potential to help boost patient quality of life, but it also offers the chance to save the NHS money and free up space by diminishing the risk of hospitalisation for unplanned emergency treatment." This statement encapsulates the strategic value of Kerendia – improving patient outcomes while simultaneously contributing to the sustainability of the health service by reducing the high costs associated with emergency admissions.
From Bayer’s perspective, this approval further solidifies Kerendia’s position as a critical therapy in cardiovascular and renal medicine. A representative from Bayer, while not explicitly quoted in the original text, would logically express satisfaction with NICE’s decision, underscoring the company’s commitment to innovation and improving patient lives. Such statements typically highlight the rigorous research and development efforts behind the drug and the company’s dedication to partnering with healthcare systems to deliver effective solutions.
Patient advocacy groups are also likely to welcome the news, as increased access to innovative treatments directly translates to improved quality of life and potentially extended lifespans for their members. They would likely emphasize the importance of having more options for a condition like HFpEF, which has historically been difficult to manage. Cardiologists and other healthcare professionals treating heart failure would view Kerendia as a valuable addition to their therapeutic arsenal, providing a new tool to manage a complex patient group, especially those who may not tolerate or respond adequately to existing therapies. The non-steroidal nature and improved selectivity would be particularly appreciated, offering greater flexibility in patient management.
Implications for Patients, the NHS, and the Pharmaceutical Sector
The approval of Kerendia carries significant implications across the healthcare ecosystem:
For Patients: The most immediate and profound impact will be on patients living with chronic heart failure with preserved or mildly reduced ejection fraction. They will gain access to a new, effective treatment option that has demonstrated the ability to reduce hospitalisations and improve cardiovascular outcomes. This translates to a better quality of life, reduced symptom burden, and a greater sense of control over their condition. For many, this could mean fewer emergency room visits, more time spent at home, and an overall improvement in their daily living. The drug’s improved tolerability profile, particularly regarding sexual side effects, may also enhance patient adherence, leading to better long-term health outcomes.
For the NHS: While the initial procurement cost of Kerendia will be a factor, the long-term benefits for the NHS are substantial. By reducing avoidable hospitalisations linked to heart failure, Kerendia has the potential to generate significant cost savings. Emergency admissions and extended hospital stays are among the most expensive aspects of heart failure management. A therapy that can effectively mitigate these events frees up valuable bed space, reduces the workload on emergency departments, and allows healthcare resources to be reallocated to other critical areas. This aligns with the NHS’s broader strategic goals of efficiency and delivering high-quality, sustainable care. The drug also contributes to a more comprehensive and robust heart failure management pathway, ultimately leading to better population health outcomes.
For the Pharmaceutical Sector and Bayer: For Bayer, this NICE recommendation further strengthens Kerendia’s market position and reinforces its cardiovascular and renal portfolio. Having secured approval for both CKD/T2D and now HFpEF/HFmrEF, Kerendia is becoming a cornerstone therapy for interconnected cardiorenal metabolic syndromes. This expands Bayer’s reach within a highly competitive therapeutic area. For the broader pharmaceutical sector, the successful development and approval of drugs like Kerendia highlight the ongoing innovation in treating complex chronic diseases. It underscores the importance of targeted therapies that address specific pathophysiological mechanisms, especially for conditions where historical treatments have been limited. The evolving treatment landscape for HFpEF, with the sequential approvals of SGLT2 inhibitors and now finerenone, showcases a dynamic and progressive field of drug development.
Looking Ahead: The Future of Heart Failure Management
The integration of Kerendia into NHS practice marks another significant step in the ongoing evolution of heart failure management. The future of treating this complex condition is likely to involve a multi-drug approach, leveraging the synergistic effects of different therapeutic classes. Combination therapies, potentially including MRAs like finerenone, SGLT2 inhibitors, ARNI (angiotensin receptor-neprilysin inhibitor) drugs, and beta-blockers, will become increasingly common to optimize patient outcomes across the spectrum of heart failure phenotypes.
Continued research and development will focus on identifying new biomarkers for earlier diagnosis, refining patient stratification to target therapies more effectively, and exploring novel mechanisms of action to address remaining unmet needs. The importance of early diagnosis and intervention cannot be overstated; identifying patients at risk and initiating appropriate treatment before significant cardiac damage occurs is crucial for preventing progression and improving long-term prognosis.
NICE’s role in evaluating and integrating these new treatments into clinical practice remains pivotal. Its rigorous assessment process ensures that only therapies demonstrating clear clinical and cost-effectiveness are adopted, safeguarding both patient interests and the sustainability of the NHS. As the scientific understanding of heart failure deepens and pharmaceutical innovation continues, patients in England can look forward to an increasingly effective and personalized approach to managing this challenging chronic condition.
